DBV Technologies

publicly owned French biopharmaceutical firm headquartered in Bagneux, France

DBVT Nasdaq ISIN FR0010417345 SEC CIK 1613780 LEI 969500PVBQFWQKVDMD80
Follow DBV Technologies Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.6M −42.9% vs same quarter last year
Net income −$64.5M −94.3% vs same quarter last year
EPS, diluted −$0.14 +41.7% vs same quarter last year
Operating cash flow −$51.5M −59% vs same quarter last year
Revenue by quarter
$511K
$800K
$1.5M
$2.8M
$636K
$900K
$700K
$1.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$200M−$150M−$100M−$50M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$147.2M
FY24$0−$114.1M
FY23$0−$72.7M
FY22$0−$96M
FY21$0−$98.1M
FY20$0−$159.7M
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23−$78.3M
FY22−$52.2M
FY21−$105M
FY20−$163.7M